Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study

An in-depth look at a study that assessed the effects of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution.

ReachMD Healthcare Image
Media formats available
  • Completing the pre-test is required to access this content.
    Pre-Survey
    Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free